Gastroenterologists traditionally view ulcerative colitis as a mucosal disorder characterized by superficial inflammatory ulcerations. However, emerging population-based evidence demonstrates that fibrotic complications in UC represent a serious and underappreciated clinical reality. Patients who experience colonic strictures, stenosis, or obstruction suffer progressive tissue damage and high morbidity. Consequently, clinicians must recognize that intestinal fibrosis is not limited to Crohn's disease. Persistent epithelial injury triggers transmural signaling that activates resident fibroblasts and myofibroblasts. These activated cells deposit excessive extracellular matrix proteins into the submucosal and muscular layers. Therefore, understanding the epidemiological patterns, risk factors, and healthcare impact of these complications is essential for modern gastroenterology practice.

Shifting Paradigms: Recognizing Fibrotic Complications in UC

Historically, medical teaching contrasted transmural Crohn's disease against superficial ulcerative colitis. Nevertheless, histopathological analyses of colectomy specimens reveal that extensive submucosal fibrosis occurs in almost all patients undergoing surgery for medically refractory colitis. When mucosal injury persists, it stimulates an abundance of potent profibrotic cytokines, notably transforming growth factor-beta. Consequently, activated myofibroblasts produce excessive extracellular matrix components, depositing thick collagen bands beneath the damaged epithelium. In addition, marked hypertrophy of the muscularis mucosae and muscularis propria accompanies this collagen expansion. These structural alterations distort colonic architecture, promoting wall stiffening and luminal narrowing. Therefore, clinicians must understand that fibrogenesis reflects a direct consequence of chronic inflammation rather than a rare anomaly. Furthermore, this structural remodeling causes intractable symptoms, such as persistent urgency and altered motility, even during endoscopic mucosal remission. Thus, evaluating fibrotic tissue changes is crucial for guiding clinical management.

Epidemiology and Key Predictors of Colonic Strictures

In a nationwide cohort study examining 6,944 patients with ulcerative colitis, researchers found that 100 individuals, or 1.4%, developed fibrotic complications. Although this rate seems modest, the clinical consequences remain severe. Multivariable regression demonstrated that older age at colitis diagnosis serves as a major independent predictor of fibrostenotic complications. Specifically, patients diagnosed between ages 41 and 65 experienced an 81% higher hazard than younger adults. Moreover, individuals diagnosed past age 65 faced an adjusted hazard ratio of 2.75. Baseline medical comorbidities also increased the risk by 73%. Notably, exposure to advanced therapies correlated with a 4.38-fold higher risk of fibrotic complications. This association indicates that aggressive, treatment-refractory inflammation strongly accelerates tissue scarring. In contrast, initial proctitis provided a 51% risk reduction, confirming the protective effect of limited disease extent. Therefore, clinicians should closely monitor older patients presenting with extensive, refractory colitis.

Healthcare Resource Utilization and Economic Burden

Intestinal strictures impose an enduring financial and structural burden on healthcare systems. Interestingly, longitudinal data show that patients with fibrotic complications generate higher medical costs long before clinicians establish a stricture diagnosis. This early cost discrepancy underscores a prolonged phase of active, refractory inflammation requiring frequent outpatient consultations. Furthermore, following a confirmed diagnosis of stenosis, healthcare utilization surges dramatically. Affected patients require significantly more emergency department visits, abdominal cross-sectional imaging procedures, and repeat surveillance endoscopies. Additionally, prescription drug costs increase because physicians frequently escalate biologic therapies or initiate targeted small molecules. When mechanical obstruction resists pharmacotherapy, hospitalizations and surgical interventions become inevitable. Total proctocolectomy, strictureplasty, or diverting stomas frequently follow, substantially increasing procedural costs. Therefore, early identification of vulnerable patients is crucial to mitigate severe morbidity and reduce sustained economic strain.

Diagnostic Imperatives: Distinguishing Fibrosis from Malignancy

When an endoscopist discovers a colonic stricture in long-standing ulcerative colitis, ruling out colorectal cancer is the highest clinical priority. Chronic extensive colitis substantially raises the risk of adenocarcinoma, which frequently presents as an obstructive stricture. Therefore, clinicians must perform meticulous evaluations, using high-definition chromoendoscopy and obtaining multiple targeted biopsies from the stricture margins. In addition, cross-sectional imaging with computed tomography or magnetic resonance enterography provides vital details on mural thickness, stratification loss, and lymphadenopathy. If the endoscope cannot traverse the narrowed segment safely, clinicians must maintain heightened clinical vigilance. Furthermore, finding dysplasia within or near the stricture demands immediate multidisciplinary surgical consultation. Even with non-malignant biopsy results, tissue sampling error remains an enduring diagnostic hazard. Consequently, regular surveillance, multidisciplinary discussions, and timely surgical referrals ensure that teams detect occult malignancies promptly.

Therapeutic Limitations and Emerging Antifibrotic Horizons

Currently approved medical therapies for ulcerative colitis—including anti-tumor necrosis factor agents, anti-integrins, and targeted small molecules—primarily suppress mucosal inflammation. However, suppressing active immune signaling does not dissolve mature submucosal scar tissue or reverse muscular layer hypertrophy. In fact, dense cross-linked collagen bundles often act as an autonomous mechanical obstacle. Consequently, pharmacotherapy alone frequently fails to resolve obstructive symptoms, compelling gastroenterologists to perform endoscopic balloon dilation or surgical resection. To overcome these therapeutic shortcomings, researchers are investigating novel antifibrotic compounds designed to inhibit mesenchymal cell activation directly. Promising targets include transforming growth factor-beta signaling inhibitors, connective tissue growth factor blockers, and fibroblast activation protein inhibitors. Additionally, investigators are validating circulating biomarkers and matrix turnover neo-epitopes to detect subclinical fibrogenesis before strictures develop. Ultimately, integrating early biomarker screening with antifibrotic agents will be crucial to prevent irreversible bowel damage.

What causes fibrotic strictures to develop in ulcerative colitis?

Chronic inflammation in ulcerative colitis triggers sustained epithelial injury and stimulates resident stromal cells. In response, activated myofibroblasts and fibroblasts deposit excess extracellular matrix, primarily type I and III collagen, within the submucosal layer. Over time, concurrent hypertrophy of the muscularis mucosae and muscularis propria compounds this tissue deposition. Consequently, the colonic wall stiffens and loses compliance, ultimately narrowing the intestinal lumen into a clinically significant, non-malignant stricture or obstruction.

Why must physicians thoroughly evaluate colonic strictures in ulcerative colitis?

Physicians must evaluate every stricture rigorously because colonic narrowing in chronic ulcerative colitis carries a heightened risk of underlying malignancy. Chronic mucosal inflammation predisposes patients to dysplasia and adenocarcinoma, which frequently mimic benign fibrostenosis. Therefore, clinicians must perform complete colonoscopic surveillance with multiple targeted biopsies across the strictured segment. In addition, if the endoscope cannot traverse the lesion or if biopsies reveal dysplasia, prompt surgical consultation is essential to exclude aggressive colonic neoplasms.

Can current biologic therapies reverse established colonic fibrosis?

Current biologic therapies and small molecules suppress active inflammatory cascades effectively, but they do not reverse mature, established fibrosis. When dense extracellular matrix remodeling and muscular hypertrophy become permanent, anti-inflammatory medications cannot dissolve the accumulated scar tissue. Consequently, symptomatic patients often require endoscopic balloon dilation to alleviate obstructive symptoms. Furthermore, if recurrent stricturing impairs bowel transit or threatens bowel perforation, surgical colectomy or strictureplasty remains necessary despite ongoing biologic treatment to ensure durable symptom relief.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice or substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

1. Shapiro I et al. Fibrotic complications in ulcerative colitis are associated with early and persistent healthcare burden. Dig Liver Dis. 2026 Nov 07. doi: undefined. PMID: 42998934.
2. de Bruyn JR, et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. J Crohns Colitis. 2018;12(8):966-976.
3. Rieder F, et al. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):340-350.
4. Dave P. Factors that Increase the Risk of Inflammatory Bowel Disease. World J Curr Med Pharm Res. 2024;6(1):322-328.